Advertisement

Topics

Current biopharma R&D costs ‘unsustainable’, warns report

07:11 EDT 20 Jun 2017 | PharmaTimes

Improving return on investment in R&D is “imperative” to the future success of global pharma and biotech companies, warns a new report by Ernst & Young.

Original Article: Current biopharma R&D costs ‘unsustainable’, warns report

NEXT ARTICLE

More From BioPortfolio on "Current biopharma R&D costs ‘unsustainable’, warns report"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...